GlassScriptPhysician profile
Cheng V Lee
NPI 1578750519
$2,545.98
in general payments reported to CMS, 2019-2025
24 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $120 · 2021: $31.03 · 2022: $142 · 2023: $658 · 2024: $890 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.69 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $533.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $257.71 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $233.47 | 2019-2025 | |
| Astellas Pharma US INC | $185.02 | 2023-2025 | Veozah |
| Lilly USA, LLC | $182.24 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $169.36 | 2019-2020 | |
| Amgen INC. | $139.75 | 2019-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.23 | 2023-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $104.16 | 2022-2024 | Quviviq |
| Abbvie INC. | $103.82 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $92.61 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $66.77 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Stryker Corporation | $66.26 | 2025 | Clottriever Bold Catheter |
| Astrazeneca Pharmaceuticals LP | $55.51 | 2019-2024 | Airsupra, Farxiga |
| Dexcom, INC. | $37.32 | 2023-2025 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $33.48 | 2023-2024 | Yupelri |
| Inspire Medical Systems, INC. | $31.79 | 2024 | Inspire |
| Avanir Pharmaceuticals, INC. | $28.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.05 | 2019 | |
| Daiichi Sankyo INC. | $21.64 | 2024 | Injectafer |
| Abbott Laboratories | $18.73 | 2023 | Freestyle Libre 3 |
| Seqirus USA INC | $18.34 | 2019 | |
| Lundbeck LLC | $15.81 | 2023 | Vyepti |
| Neos Therapeutics, LP | $14.08 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheng Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.